cGAS‐STING pathway agonists are promising vaccine adjuvants
Medicinal Research Reviews · 2024-07 · 44 (4) · 1768-1799
DOI: 10.1002/med.22016 ↗At a glance
Übersichtsarbeit in Medicinal Research Reviews, published online on 2024-02-07. Written by Xinyu Tian and 3 co-authors. Institution: Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Centre for Geriatrics, West China…. Major MEDLINE topics: Nucleotidyltransferases, Membrane Proteins. Cited 86 times so far (Crossref); 208 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Science Foundation for Excellent Young Scholars (32122052) and National Natural Science Foundation Regional Innovation and Development (No. U19A2003)..
Abstract (original language)
Adjuvants are of critical value in vaccine development as they act on enhancing immunogenicity of antigen and inducing long‐lasting immunity. However, there are only a few adjuvants that have been approved for clinical use, which highlights the need for exploring and developing new adjuvants to meet the growing demand for vaccination. Recently, emerging evidence demonstrates that the cGAS‐STING pathway orchestrates innate and adaptive immunity by generating type I interferon responses. Many cGAS‐STING pathway agonists have been developed and tested in preclinical research for the treatment of cancer or infectious diseases with promising results. As adjuvants, cGAS‐STING agonists have demonstrated their potential to activate robust defense immunity in various diseases, including COVID‐19 infection. This review summarized the current developments in the field of cGAS‐STING agonists with a special focus on the latest applications of cGAS‐STING agonists as adjuvants in vaccination. Potential challenges were also discussed in the hope of sparking future research interests to further the development of cGAS‐STING as vaccine adjuvants.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China.
ORCID profiles: Xiawei Wei
Funding
- National Science Foundation for Excellent Young Scholars (32122052) and National Natural Science Foundation Regional Innovation and Development (No. U19A2003).
Cite
APA
Tian, X., Ai, J., Tian, X., & Wei, X. (2024). cGAS‐STING pathway agonists are promising vaccine adjuvants. Medicinal Research Reviews, 44(4), 1768-1799. https://doi.org/10.1002/med.22016
Vancouver
Tian X, Ai J, Tian X, Wei X. cGAS‐STING pathway agonists are promising vaccine adjuvants. Medicinal Research Reviews. 2024;44(4):1768-1799. doi:10.1002/med.22016
BibTeX
@article{Tian2024,
author = {Tian, Xinyu and Ai, Jiayuan and Tian, Xiaohe and Wei, Xiawei},
title = {cGAS‐STING pathway agonists are promising vaccine adjuvants},
journal = {Medicinal Research Reviews},
year = {2024},
volume = {44},
number = {4},
pages = {1768--1799},
doi = {10.1002/med.22016}
}
EUVIMED